Stereotaxis
Stereotaxis' revenue rose 20.3% to $32 million in fiscal 2025. Its operating margin was −68.3%, up from −91.9% a year earlier. Free cash flow was −$14 million. The diluted share count rose 6.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Stereotaxis lost money in fiscal 2025: a net loss of $22 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 39 | 28 | — | 12 | 13 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 3.9x | 3.0x | 2.5x | 1.2x | 1.5x |
| Quick ratio | 3.5x | 2.5x | 1.9x | 0.8x | 1.1x |
Cash flow
Projections
Project Stereotaxis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Stereotaxis says to expect
- Quarterly adjusted operating expenses going forward
Adjusted operating expenses, excluding non-cash and one-time items, are expected to approximate $8 million per quarter going forward.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $135,754 of Stereotaxis shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Arun Swarup MenawatDirector | Bought | 121,561 | $0.82 | $99,984 | Form 4 |
| Nov 17, 2026 | David BenferDirector | Bought | 30,000 | $0.83 | $24,870 | Form 4 |
| Nov 17, 2026 | Paul J IsaacDirector | Bought | 300 | $0.80 | $240 | Form 4 |
| Nov 16, 2026 | Paul J IsaacDirector | Bought | 13,000 | $0.82 | $10,660 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −40.4% | −31.1% | −22.3% |
| Altman Z'' | −41.33 | −41.89 | −37.38 |
| Accruals ratio | −24.3% | −35.1% | −16.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Fail | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Stereotaxis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Stereotaxis | FY25 | 20.3% | −68.3% | −42.5% | — | — | — | |
| electroCore | FY25 | 27.2% | −41.1% | −25.8% | — | — | — | Compare |
| Precision Optics Corporation | FY26 | 65.2% | −11.1% | −6.3% | −22.8% | — | 5 | Compare |
| Orchestra BioMed | FY25 | 1,169.2% | −154.7% | −147.7% | — | — | 5 | Compare |
| Senseonics | FY25 | 56.9% | −193.8% | −170.9% | — | — | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 32 | 31 | 29 | 29 | 27 | 35 | 28 | 27 | 27 | 32 |
| Revenue growth | −14.6% | −3.2% | −5.8% | −1.5% | −7.9% | 31.5% | −19.6% | −4.9% | 0.6% | 20.3% |
| Gross profit | 25 | 20 | 24 | 23 | 19 | 23 | 18 | 15 | 15 | 17 |
| Research and development | 6 | 7 | 8 | 9 | 8 | 10 | 11 | 10 | 10 | 9 |
| Operating income | −6 | −6 | −2 | −5 | −7 | −13 | −19 | −22 | −25 | −22 |
| Net income | −5 | −6 | 0 | −5 | −7 | −11 | −18 | −21 | −24 | −22 |
| Diluted EPS (US$) | −0.54 | −0.32 | −0.03 | −0.10 | −0.11 | −0.16 | −0.26 | −0.27 | −0.30 | −0.25 |
| Diluted shares (millions) | 22 | 23 | 52 | 63 | 73 | 76 | 76 | 81 | 85 | 91 |
| Cash flow | ||||||||||
| Cash from operations | −7 | −5 | −2 | −5 | −4 | −3 | −8 | −9 | −8 | −14 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Free cash flow | −7 | −5 | −3 | −5 | −4 | −4 | −11 | −10 | −9 | −14 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | 1 | 1 | 3 | 9 | 11 | 11 | 10 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 8 | 4 | 11 | 30 | 44 | 39 | 28 | — | 12 | 13 |
| Debt incl. finance leases | — | — | — | — | 2 | — | — | — | — | — |
| Total assets | 21 | 11 | 18 | 44 | 56 | 61 | 53 | 42 | 47 | 52 |
| Total liabilities | 36 | 31 | 11 | 15 | 15 | 22 | 22 | 20 | 35 | 34 |
| Shareholders' equity | −22 | −27 | 1 | 23 | 35 | 34 | 26 | 16 | 6 | 14 |
| Margins and ratios | ||||||||||
| Gross margin | 76.6% | 65.5% | 80.5% | 78.8% | 71.2% | 66.3% | 65.6% | 55.5% | 54.2% | 52.7% |
| Operating margin | −20.0% | −19.0% | −8.4% | −16.7% | −25.2% | −36.8% | −66.7% | −81.6% | −91.9% | −68.3% |
| Net margin | −16.4% | −18.9% | 0.4% | −15.9% | −25.0% | −30.6% | −65.0% | −77.4% | −89.3% | −66.8% |
| Free cash flow margin | −21.7% | −15.3% | −9.6% | −16.1% | −13.4% | −12.4% | −38.4% | −35.5% | −31.7% | −42.5% |
| Rule of 40 (growth + FCF margin) | −36.3% | −18.4% | −15.3% | −17.6% | −21.3% | 19.1% | −58.0% | −40.4% | −31.1% | −22.3% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | −38.1% | −23.2% | −31.3% | −60.8% | −97.0% | −214.5% | −221.3% |
| Return on assets | −26.5% | −37.2% | 0.8% | −14.8% | −13.4% | −18.4% | −32.0% | −43.5% | −54.3% | −43.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |